8-K: 60 Degrees Pharma Faces Nasdaq Delisting

60 Degrees Pharmaceuticals, Inc. received a notice from Nasdaq regarding the delisting of its common stock and warrants due to a failure to maintain the minimum bid price and a recent reverse stock split.

Summary

• 60 Degrees Pharmaceuticals, Inc. received a notice from Nasdaq on January 20, 2026, stating its common stock and warrants will be delisted from The Nasdaq Capital Market.
• The delisting is due to the company's failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• The company is not eligible for the standard 180-calendar-day compliance period because it effected a 1-for-5 reverse stock split on February 24, 2025, within the prior one-year period, leading to immediate delisting under Nasdaq Listing Rule 5810(c)(3)(A)(iv).
• Warrants are also subject to delisting as the underlying common stock will no longer be listed on Nasdaq, per Nasdaq Listing Rule 5560(a).
• The company has paid a $20,000 hearing fee and requested an appeal with Nasdaq, which temporarily stays the suspension of trading and the filing of Form 25-NSE.
• There is no assurance that the Nasdaq Panel will grant the company's request for continued listing.

Sentiment

Score: 2

Explanation: The filing indicates a severe negative event with the Nasdaq delisting notice and immediate delisting determination, offset only slightly by the company's appeal, which has no assurance of success.

Positives

• The company has requested an appeal with Nasdaq, which temporarily stays the suspension of trading and the filing of Form 25-NSE pending the Panel's decision.

Negatives

• Nasdaq has determined to delist the company's common stock and warrants.
• The company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
• The company is not eligible for a compliance period due to a reverse stock split within the prior year, leading to immediate delisting.
• There is no assurance that the appeal for continued listing will be granted.

Risks

• The company's common stock and warrants may be delisted from The Nasdaq Capital Market.
• Delisting could significantly reduce the liquidity and marketability of the company's securities.
• The appeal process may not result in the company's continued listing on Nasdaq.
• Failure to meet Nasdaq's minimum bid price requirement indicates underlying financial or market performance challenges.

Future Outlook

The company's future listing on Nasdaq is uncertain and depends entirely on the outcome of its appeal to the Nasdaq Hearings Panel. There is no guarantee that the request for continued listing will be granted.

Management Comments

• The company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Industry Context

Delisting from a major exchange like Nasdaq can severely impact a pharmaceutical company's ability to raise capital, attract institutional investors, and maintain public visibility. For smaller pharmaceutical companies, maintaining listing standards is crucial for funding drug development and operations. This event highlights the challenges faced by some smaller biotech/pharma firms in meeting market capitalization and share price requirements, especially after reverse stock splits.

Comparison to Industry Standards

• Maintaining a minimum bid price of $1.00 is a standard Nasdaq listing requirement (Rule 5550(a)(2)) for all listed companies.
• The ineligibility for a compliance period after a reverse stock split within a year (Rule 5810(c)(3)(A)(iv)) is a specific Nasdaq rule designed to prevent companies from repeatedly using splits to temporarily meet listing standards without fundamental improvement. This rule applies uniformly across industries.
• Many small-cap biotechnology and pharmaceutical companies face similar challenges in maintaining listing compliance, particularly regarding bid price, due to the high-risk, long-development cycle nature of their business and often limited revenue streams.

Stakeholder Impact

• Shareholders face significant risk of reduced liquidity, marketability, and potential loss of investment value if the stock is delisted from Nasdaq.
• Investors may find it harder to trade the company's shares and warrants, potentially leading to a wider bid-ask spread and lower valuations.
• Delisting could hinder the company's ability to raise future capital, which is critical for pharmaceutical development.

Next Steps

• The Nasdaq Hearings Panel will review the company's appeal.
• The company awaits the Panel's decision regarding its request for continued listing.

Key Dates

Recommendation

The immediate delisting determination from Nasdaq, coupled with the company's ineligibility for a compliance period due to a recent reverse stock split, presents a critical threat to the company's public market access and investor confidence. While an appeal is underway, there is no assurance of success. Delisting would severely impair liquidity and access to capital, making the stock a high-risk investment with significant downside potential. Investors should consider exiting their positions.

Keywords

Nasdaq delisting, minimum bid price, reverse stock split, 8-K filing, pharmaceuticals, stock warrants, corporate governance, listing rules, appeal